| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,296.22 | 872.39 | 419 | 330.42 | 324.85 |
| Total Expenses | 1,101.70 | 769.53 | 430.05 | 396.53 | 261.73 |
| Profit Before Tax | 194.52 | 102.86 | -11.05 | -66.11 | 63.12 |
| Profit After Tax | 134.36 | 91.01 | -16.89 | -67.12 | 30.69 |
| Operating Profit After Depreciation | 231.31 | 134.12 | 7.91 | -56.39 | 72.49 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 327.15 | 307.32 | 199.38 | 192.98 | 188.24 |
| Total Non Current Assets | 388.06 | 346.32 | 248.12 | 231.12 | 198.46 |
| Total Current Assets | 1,063.37 | 763.17 | 501.59 | 328.40 | 339.79 |
| Total Assets | 1,451.43 | 1,109.49 | 749.70 | 559.52 | 538.25 |
| Total Shareholder's Fund | 540.98 | 385 | 286.38 | 305.40 | 374.15 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 159.18 | 21.01 | -74.75 | -62.63 | 61.67 |
| Net Cash Used In Investing Activities | -65 | -68.38 | -32.31 | -45.91 | -46.09 |
| Net Cash Used In Financing Activities | -39.81 | 43.55 | 122.81 | 63.05 | 51.50 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,093.52 | 656.94 | 419 | 417.41 | 342.08 |
| Total Expenses | 870.24 | 622.87 | 430.05 | 400.49 | 256.70 |
| Profit Before Tax | 223.28 | 34.07 | -11.05 | 16.92 | 85.39 |
| Profit After Tax | 167.54 | 24.35 | -16.89 | 16.68 | 52.96 |
| Operating Profit After Depreciation | 257.57 | 64.60 | 7.91 | 25.95 | 94.39 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 259.56 | 231.84 | 199.38 | 180.62 | 176.94 |
| Total Non Current Assets | 390.61 | 446.09 | 248.12 | 280.31 | 216.06 |
| Total Current Assets | 950.32 | 570.51 | 501.59 | 398.03 | 353.53 |
| Total Assets | 1,340.94 | 1,016.60 | 749.70 | 678.34 | 569.60 |
| Total Shareholder's Fund | 667.79 | 475.87 | 286.38 | 428.61 | 411.46 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 29.65 | 83.20 | -74.75 | -71.10 | 46.85 |
| Net Cash Used In Investing Activities | -10.22 | -130.36 | -32.31 | -43.20 | -28.88 |
| Net Cash Used In Financing Activities | -34.05 | 45.86 | 122.81 | 65.22 | 52.18 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 513.92 | 475.53 | 412.02 | 352.49 | 358.15 |
| Total Expenses | 395.21 | 367.41 | 317.72 | 273.39 | 285.67 |
| Profit Before Tax | 98.69 | 90.59 | 71.71 | 59.54 | 51.07 |
| Profit After Tax | 76.79 | 72.80 | 53.85 | 43.30 | 36.25 |
| Operating Profit after Depreciation | 121.32 | 111.91 | 95 | 79.73 | 72.58 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 389.88 | 301.71 | 336.47 | 278.03 | 300.81 |
| Total Expenses | 283.71 | 239.47 | 257.36 | 214.88 | 239.50 |
| Profit Before Tax | 94.18 | 49.52 | 61.63 | 47.44 | 53.93 |
| Profit After Tax | 70.02 | 37.18 | 45.81 | 35.15 | 40.27 |
| Operating Profit after Depreciation | 109.75 | 66.54 | 80.62 | 64.59 | 73.28 |
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
| Fund Name | AUM |
|---|---|
| Motilal Oswal Small Cap Fund | 3.80% |
| Bajaj Finserv Small Cap Fund | 3.37% |
| Motilal Oswal Focused Fund | 3.26% |
| Kotak Manufacture in India Fund | 3.05% |
| Canara Robeco Manufacturing Fund | 2.28% |
Rubicon Research surged 12.55% to Rs 1,130 after the company's consolidated net profit soared 100% to Rs 76.78 crore on 43.49% increase in revenue from operations to Rs 513.91 crore in Q4 FY26 over Q4 FY25.
01 Jun 2026, 11:01 am
Of Rs 1.5 per share
30 May 2026, 05:34 pm
29 May 2026, 08:25 pm
On 29 May 2026
25 May 2026, 09:40 am
Rubicon Research rose 1.02% to Rs 879 after it has announced the acquisition of an 85% equity stake in Arinna Lifesciences, a branded pharmaceutical marketing company focused on the CNS and neuro-psychiatric segment in India.
17 Apr 2026, 09:20 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.